...
首页> 外文期刊>The Journal of Urology >Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry.
【24h】

Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry.

机译:通过表面增强激光解吸/电离质谱法鉴定肾细胞癌的2种血清生物标志物。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: Surface enhanced laser desorption/ionization mass spectrometry can generate robust information from a small amount of clinical samples such as serum and plasma. In this study we identified novel diagnostic biomarkers of renal cell carcinoma (RCC) by large-scale serum protein profiling using surface enhanced laser desorption/ionization mass spectrometry. MATERIALS AND METHODS: Proteomic spectra were generated by a time of flight mass spectrometer from a set of training samples (21 patients with RCC and 24 healthy volunteers) and another set of validation samples (19 patients with RCC, 20 healthy volunteers and 5 patients with pyelonephritis). Information on the peaks (intensity and m/z) was extracted from the mass spectra using newly developed algorithms, and the Mann-Whitney's U test and linear support vector machine were used to identify the peaks distinguishing RCC samples from the controls. RESULTS: Two peaks with molecular masses of 4,151 and 8,968 m/z were selected as significantly more prominent in RCC samples (p <0.01) among the 3,539 peaks in the range of 3,000 to 30,000 m/z obtained from the training samples. Simultaneous recognition of these 2 biomarkers was shown to have a sensitivity of 89.5% for the diagnosis of RCC and an overall specificity of 80.0% (95% [19 of 20] of healthy volunteers and 20% [1 of 5] of patients with pyelonephritis) in the blinded validation samples, and to allow detection of RCC in stage I (UICC) in 88.9% (16 of 18) of the cases. CONCLUSIONS: We identified 2 serum biomarkers potentially useful for the early diagnosis of RCC. This finding warrants a further large-scale multi-institutional analysis for clinical evaluation of the diagnostic significance of these biomarkers.
机译:目的:表面增强的激光解吸/电离质谱可以从少量的临床样本(如血清和血浆)中生成可靠的信息。在这项研究中,我们通过使用表面增强的激光解吸/电离质谱技术对血清蛋白进行大规模分析,确定了肾细胞癌(RCC)的新型诊断生物标志物。材料与方法:蛋白质组谱是由飞行时间质谱仪从一组训练样本(21例RCC患者和24名健康志愿者)和另一组验证样本(19例RCC患者,20名健康志愿者和5例经验证的样本)中生成的。肾盂肾炎)。使用新开发的算法从质谱图中提取有关峰的信息(强度和m / z),然后使用Mann-Whitney的U检验和线性支持向量机来识别将RCC样品与对照区分开的峰。结果:在从训练样品中获得的3,000到30,000 m / z范围内的3,539个峰中,在RCC样品中选择了两个分子量分别为4,151和8,968 m / z的峰(p <0.01)。同时识别这两种生物标志物对RCC的诊断灵敏度为89.5%,总特异性为80.0%(95%[20名患者中的19名]健康志愿者和20%[5名患者中的1名]肾盂肾炎),并允许在88.9%(18个中的16个)案例中检测出第一阶段的RCC(UICC)。结论:我们确定了2种血清生物标志物,可能对RCC的早期诊断有用。这一发现为进一步评估这些生物标志物的诊断意义提供了进一步的大规模多机构分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号